Clinical Trial

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Study acronym: CAPTIVATE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure. CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-09-21; most recent amendment 2026-03-26.
Status change: Not Yet Recruiting → Recruiting 2024-08-20
Trial Details
NCT Number NCT06058585
Lead Sponsor The George Institute
Conditions Chronic Kidney Diseases
Enrollment 1,000 participants
Start Date 2024-09-04
Primary Completion 2028-08-30 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-01